Form SC 14D9/A Sagent Pharmaceuticals, Filed by: Sagent Pharmaceuticals, Inc.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
(Amendment No. 1)
Solicitation/Recommendation Statement
Under Section 14(d)(4) of the Securities Exchange Act of 1934
Sagent Pharmaceuticals, Inc.
(Name of Subject Company)
Sagent Pharmaceuticals, Inc.
(Name of Person Filing Statement)
Common Stock, par value $0.01 per share
(Title of Class of Securities)
786692103
(CUSIP Number of Class of Securities)
Allan Oberman
Chief Executive Officer
Sagent Pharmaceuticals, Inc.
1901 N. Roselle Road, Suite 700
Schaumburg, Illinois 60195
(847) 908-1600
(Name, address and telephone number of person authorized to receive notices and communications
on behalf of the persons filing statement)
With copies to:
George P. Stamas
William B. Sorabella
Alexander D. Fine
Kirkland & Ellis LLP
601 Lexington Avenue
New York, New York 10022
(212) 446-4800
¨ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
Purpose of Amendment.
This Amendment No. 1 (this Amendment) amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 of Sagent Pharmaceuticals, Inc. (the Company) filed with the Securities and Exchange Commission (the SEC) on August 1, 2016 (the Schedule 14D-9). The Schedule 14D-9 relates to the tender offer by Shepard Vision, Inc., a Delaware corporation (Purchaser) and a direct wholly owned subsidiary of Nichi-Iko Pharmaceutical Co., Ltd., a Japanese corporation (Parent), made pursuant to an Agreement and Plan of Merger, dated as of July 10, 2016, among Parent, Purchaser and the Company (as it may be amended or supplemented from time to time), to purchase all of the outstanding shares of the Companys common stock, par value $0.01 per share (Shares), at a purchase price of $21.75 per Share, net to the seller in cash, without interest (less any required withholding taxes), upon the terms and subject to the conditions set forth in the Offer to Purchase, dated August 1, 2016 (as it may be amended or supplemented from time to time, the Offer to Purchase), and in the related Letter of Transmittal (as it may be amended or supplemented from time to time, which together with the Offer to Purchase is referred to as the Offer). The Offer is described in a Tender Offer Statement on Schedule TO (as amended or supplemented from time to time) filed by Purchaser and Parent with the SEC on August 1, 2016.
Except as otherwise set forth below, the information set forth in the Schedule 14D-9 remains unchanged and is incorporated by reference as relevant to the items in this Amendment. Capitalized terms used and not defined herein shall have the meanings assigned to such terms in the Schedule 14D-9. This Amendment is being filed to reflect certain updates as reflected below.
Item 8. | Additional Information. |
Item 8 of the Schedule 14D-9 is hereby amended and supplemented by deleting the second paragraph under the heading Regulatory Approvals on page 61 of the Schedule 14D-9 and replacing it with the following paragraphs:
The condition to the Offer requiring that any waiting period under the HSR Act applicable to the purchase of Shares pursuant to the Offer and the consummation of the Merger shall have expired or been terminated has been satisfied by the expiration of the HSR Act waiting period, effective August 8, 2016 at 11:59 p.m. (Eastern Time). The Offer continues to be subject to the remaining conditions set forth in the Offer to Purchase.
On August 9, 2016, Parent issued a press release announcing the termination of the waiting period, a copy of which is filed as Exhibit (a)(5)(vii) to the amendment to the Schedule TO filed with the SEC on August 9, 2016 (the Schedule TO/A) and is incorporated herein by reference.
Item 9. | Exhibits. |
Item 9 of the Schedule 14D-9 is hereby amended and supplemented by adding the following thereto:
Exhibit |
Description | |
(a)(5)(G) | Press Release issued by Parent, dated August 9, 2016 (incorporated herein by reference to Exhibit (a)(5)(vii) to the Schedule TO/A filed with the SEC on August 9, 2016). |
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Sagent Pharmaceuticals, Inc. | ||
By: | /s/ Allan Oberman | |
Name: Allan Oberman | ||
Title: Chief Executive Officer |
Dated: August 9, 2016
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: RH, Estee Lauder rise; Tesla falls
- MorphoSys AG (MOR) Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis
Create E-mail Alert Related Categories
SEC FilingsRelated Entities
14D9Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!